BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
BNB$577.36-1.84%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
BNB$577.36-1.84%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
Caught between U.S. reshoring efforts and China’s manufacturing leverage, Apple’s trillion-dollar momentum may hinge on how fast ‘Apple Intelligence delivers.
As volatile U.S. trade policy exposes a critical vulnerability to China's rare earth dominance, investors are turning to domestic producers like MP Materials and Arafura Rare…
Policy tailwinds and precision medicine breakthroughs are pushing healthcare stocks like Tempus AI and CRISPR Therapeutics into a new era of growth.
With Edge Autonomy and Hera Systems under its belt, Redwire is assembling the tools to lead the new frontier of defense-aligned space tech.
Lockheed’s defense backlog, Pfizer’s biotech expansion, and Schlumberger’s energy contracts make for safe and potentially lucrative dividend plays heading into year-end.
In an economy divided between winners and laggards, these three stocks remain on the winning side of the Fed’s rate-cutting cycle.
With LLMs diagnosing and robots operating, the future of medicine is unfolding, and investors can buy in now.
AMD stock dropped sharply after Seaport Research downgraded shares to Neutral, citing slower AI accelerator adoption, supply chain issues, and competitive pressures.
Palantir’s $372.6 billion valuation rests on a price-to-earnings ratio over 15 times higher than Amazon’s.
Tesla stock gains 3.87% following robotaxi permit approval in Texas and UK energy license application.
Palantir’s role in U.S. public-private governance has never been clearer, and PLTR stock is moving in lockstep.
Amazon stock crashes 7.94% in premarket despite beating Q2 earnings expectations.
Ozempic-famed Novo Nordisk took over a $70 billion wipeout off its market value this week. Is this the beginning of a trend, or a great opportunity?